Summary Background Psoriasis is a chronic disease requiring long-term therapy. Objectives Physician- and patient-reported outcomes were evaluated through week 252 in VOYAGE 1 and VOYAGE 2. Methods In total, 1829 patients were randomized at baseline to receive guselkumab 100 mg every 8 weeks, placebo or adalimumab. Patients receiving placebo crossed over to guselkumab at week 16.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by B. Strober
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results up to 32 weeks from a randomised, phase 3 study
RESEARCH LETTER A.S. Van Voorhees Corresponding Author vanvooas@evms.edu orcid.org/0000-0003-3863-3842 Eastern Virginia Medical School, Norfolk, VA, USA Correspondence: A.S. Van Voorhees. Email: vanvooas@evms.edu Contribution: Investigation (equal), Writing - original draft (equal), Writing - review & editing (equal) Search for more papers by this author Z.
Dynamic genetic regulation of gene expression during cellular differentiation
Download and print this article for your personal scholarly, research, and educational use. Buy a single issue of Science for just $15 USD.
Long‐term safety of adalimumab in adult patients with plaque psoriasis
Summary Adalimumab is a powerful drug used to treat psoriasis, that has been specially designed to mimic normal human molecules, and for this reason it is classed as a ‘biological’ drug. It reduces inflammation by inhibiting the activity of a chemical ‘cytokine’ in the body called ‘tumour necrosis factor alpha’ (TNF‐alpha). The aim of this study, from the USA, was to assess long‐term safety for patients with psoriasis receiving adalimumab.
British Journal of Dermatology
Summary 阿达木单抗是一种用于治疗银屑病的强力药物,专门被设计模拟正常人体分子,因此被归类为一种“生物”药。它通过抑制身体中一种被称为“肿瘤坏死因子 α” (TNF‐α) 的化学“细胞因子”的活动性来减轻炎症。此项来自美国的研究的目的是评估接受阿达木单抗治疗银屑病患者中的长期安全性。作者们调查了来自 3727 名接受此药患者的数据,作为记录了不良事件(AE,指用药时的不良副作用)的 18 项不同临床试验的一部分。总体而言,5,429.7 名患者‐年龄中有 16,536 例 AE(每 100 患者‐年龄有 304.6 例 AE)。患者‐年龄 (PY) 指患者的数量乘以他们被纳入此研究中的时间长度。最常见的 AE 是鼻咽炎(一种常见的喉部主诉)、上呼吸道感染和头痛(分别为 23.7、12.9 和 7.9 例 AE 每 100 PY)。严重感染、结核和机会性感染的发生率分别为 1.8、0.3 和 0.02 例 AE 每 100 PY。不包括非黑色素瘤性皮肤癌 (NMSC) 的恶性肿瘤(癌症)的发生率为 0.8 例 AE 每 100 PY。NMSC 和黑色素瘤的发生率分别为 0.6...
Benefit‐risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials
Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor. It has been investigated in patients with moderate to severe chronic plaque psoriasis. To consider the benefits and risks of tofacitinib in moderate to severe psoriasis.
Comprehensive Long‐Term Safety of Adalimumab from Eighteen Clinical Trials in Adult Patients With Moderate to Severe Plaque Psoriasis
Adalimumab (Humira®; AbbVie Inc., USA) is a fully human monoclonal antibody specific for tumour necrosis factor‐α approved to treat adults with moderate‐to‐severe chronic plaque psoriasis. To assess long‐term safety for patients with psoriasis receiving adalimumab in clinical studies Adalimumab safety data from adults with psoriasis who received ≥1 adalimumab dose in 18 clinical trials were evaluated. Adalimumab was delivered subcutaneously in all treatment regimens.
No Elevated Risk for Depression, Anxiety, or Suicidality with Secukinumab in a Pooled Analysis of Data from 10 Clinical Studies in Moderate-to-Severe Plaque Psoriasis - Strober - 2017 - British Journal of Dermatology - Wiley Online Library
Concerns have emerged over the potential for brodalumab, a monoclonal antibody that binds to the human interleukin (IL)-17 receptor A and blocks the activity of multiple IL-17 isoforms, to increase risk of suicidal ideation and behaviour. Although the validity of this association has been questioned,1,2 brodalumab has a boxed warning regarding suicidality in its US label and is only available through a Risk Evaluation and Mitigation Strategy.
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis - Strober - 2018 - British Journal of Dermatology - Wiley Online Library
Conflicts of interest: B.E.S. has received honoraria for serving as a consultant and advisory board member for AbbVie, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, LEO Pharma, Medac, Novartis, Pfizer, Stiefel/GlaxoSmithKline, Sun Pharma, UCB and Valeant; has received payments (to the University of Connecticut) as an investigator for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck and Novartis; has received fees as a scientific director for the...
Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients - Papp - 2017 - British Journal of De
ABP 501, an FDA- and EMA-approved biosimilar, is highly similar to adalimumab in structure, function, and pharmacokinetics. Patients were randomised (1:1) to receive ABP 501 or adalimumab 40 mg every 2 weeks for 16 weeks. At Week 16, patients with ?50% improvement from baseline in psoriasis area-and-severity index score (PASI) were eligible to continue to Week 52.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with B.
Contact B., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack